D. A. Durnov

D. A. Durnov

Auto-generated profile, based on publicly available information

D. A. Durnov

Oncology Department, V.I. Razumovsky Saratov State Medical University, Saratov, Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2026 in Russian Open Medical Journal
Verified
Journal Article
Closed access
RFRoman Fomkin
Roman Fomkin
TKTatiana Kalyuta
Tatiana Kalyuta
AFAlexander Fedonnikov
Alexander Fedonnikov
VPVladimir Popkov
Vladimir Popkov
OFOlga Fomkina
Olga Fomkina
DDDenis Durnov
Denis Durnov
This first-in-human Phase I study assessed the safety and tolerability of the industrial-grade batch of AV-22 dry medicinal extract (Gratiola officinalis L.) (Developing organization: Saratov State Medical University named after V.I. Razumovsky, Ministry of Health of Russia). Objective — To evaluate the safety, tolerability, and maximum tolerated dose (MTD) of a single oral dose of AV 22 in patients with advanced genitourinary cancers. Material and Methods — An open-label, single-center, dose-escalation study was conducted using the classic 3+3 design [12]. Twenty patients with advanced genitourinary cancers were sequentially enrolled in five dose cohorts (125, 250, 375, 500, and 625 mg). Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Tumor response was assessed at day 28 using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Pharmacokinetic analyses quantified plasma concentrations of verbascoside, cucurbitacin D, cucurbitacin E, and cucurbitacin I after oral administration. Concentrations were quantified using a validated method of high-performance liquid chromatography with a mass-selective detector (HPLC-MS/MS) with a linear range of 1-1000 ng/mL (lower limit of quantification (LLOQ): 1 ng/mL). Serial blood samples for pharmacokinetic analysis were collected before and after drug administration at designated time points: 0.5, 1, 3, 6, 9, 12, 15, 18, 24, and 36 hours, as well as on days 7, 14, and 28 (all samples obtained in the morning after an overnight fast). Results — All 20 patients completed the observation protocol (mean age =65.8±9.6 years). No dose limiting toxicity (DLT) or serious adverse events were reported, and the maximum tolerated dose (MTD) was not reached at any dose level up to 625 mg. Plasma concentrations of all analyzed active components (verbascoside, cucurbitacins D, E, and I) were below the lower limit of quantification (LLOQ=1 ng/mL) at all sampling time points, precluding the calculation of standard pharmacokinetic parameters (e.g., AUC, Cₘₐₓ, Tₘₐₓ, t₁/₂). Statistically significant changes in individual laboratory parameters (e.g., hemoglobin, thrombin time, and total bilirubin) were small in magnitude and were not accompanied by clinically significant deviations. Follow-up computed tomography or magnetic resonance imaging (CT/MRI) was performed in all patients on day 28: all 20 patients (100%) achieved stable disease, with no partial or complete responses or progressive disease. Conclusion — A single 125-625 mg dose of AV-22 exhibited a favorable safety profile and tolerability in patients with advanced genitourinary cancers. The data obtained justify further studies with multiple doses and extended biomarker monitoring.

23 June 2021 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ATA. I. Tarasenko
A. I. Tarasenko
ARA. N. Rossolovskiy
A. N. Rossolovskiy
OBO. L. Berezinets
O. L. Berezinets
DDD. A. Durnov
D. A. Durnov
EPE. B. Popyhova
E. B. Popyhova
VPV. M. Popkov
V. M. Popkov
Purpose of the study.To determine the association of individual biomolecular markers of oncogenesis MMP‑2, MMP‑9 and the inhibitor of metalloproteinases TIMP‑1 with the risk of tumor invasion and metastasis in the early and late postoperative period in various types of surgical treatment of RCC.Materials and methods.The study prospectively included medical data of 60 patients with kidney cancer with T1-3N0 M0 who received surgical treatment at the Urology Clinic of the S.R.Mirotvortsev Design Bureau of the SSMU from 2016 to 2019. The patients were divided into 3 groups: 1st group included 20 patients who underwent kidney resection for elective indications, with tumors of the renal parenchyma; 2nd group – 20 patients who underwent radical nephrectomy by laparoscopic approach; Group 3-20 patients who underwent radical nephrectomy with lumbotomy access. All patients being in the early (7-10th day) and long-term postoperative period (after 1 and 2 years) by solid-phase ELISA, on a StatFax 4200 analyzer using eBiosence and Cloud-Clone Corp reagent kits, a study was made on the basis of the concentration in the blood serum of markers of oncogenesis MMP‑2, MMP‑9 and TIMP‑1 metalloproteinase inhibitor.Results.In all groups of patients with RCC, an initial increase in the concentration of MMP‑9 was revealed compared to the control (p≤0.05). According to the results of the ROC analysis, this indicator has a high specificity and sensitivity in terms of predicting RCC at the preoperative stage. The highest sensitivity and specificity for detecting tumor progression was demonstrated by matrix metalloproteinases: MMP‑2 – sensitivity 96 %, specificity 67 % (cut-off point 357.5 pg/ml) and MMP‑9 – sensitivity 87.5 % and specificity 62 % (cut-off point 958 ng/ml). At the same time, TIMP‑1 showed less significant indicators – sensitivity and specificity (74 % and 60 %, respectively) with a cut-off point of 0.49 ng/ml.Conclusion.Serum MMP‑2 and MMP‑9 are a marker of a poor prognosis for the progression of RCC. Elevated levels of MMP‑9 in the blood serum of RCC patients before and after various types of surgical treatment reflect the individual characteristics of the patient’s body and the tumor process. Dynamic monitoring of the level of markers of oncogenesis in patients with RCC allows a personalized approach to the choice of the scope and method of surgical treatment of RCC.